LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

LLY

1,021.52

+0.37%↑

JNJ

195.34

+0.5%↑

ABBV

232.46

-0.34%↓

UNH

332.18

-2.03%↓

AZN

88.54

+0.99%↑

Search

Artivion Inc

Cerrado

SectorSalud

45.46 -4.5

Resumen

Variación precio

24h

Actual

Mínimo

45.04

Máximo

47.43

Métricas clave

By Trading Economics

Ingresos

-14M

6.5M

Ventas

416K

113M

BPA

0.16

Margen de beneficio

5.734

Empleados

1,600

EBITDA

1.1M

17M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+8.57% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-25M

2.1B

Apertura anterior

49.96

Cierre anterior

45.46

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

171 / 374 Clasificación en Healthcare

Artivion Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

13 nov 2025, 21:34 UTC

Ganancias

Applied Materials 4Q Sales Fall; Forecasts Higher Demand in 2H26

13 nov 2025, 23:45 UTC

Charlas de Mercado

Nikkei May Fall After Wall Street's Weakness -- Market Talk

13 nov 2025, 23:42 UTC

Adquisiciones, fusiones, absorciones

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 4th Update

13 nov 2025, 23:41 UTC

Charlas de Mercado

Gold Edges Higher on Possible Dip-Buying -- Market Talk

13 nov 2025, 23:24 UTC

Ganancias

JBS NV: Robust U.S. Beef Demand Supported 3Q North America Sales >JBS

13 nov 2025, 23:24 UTC

Ganancias

JBS NV: Live Cattle Prices Have Remained High, Pressuring Profitability >JBS

13 nov 2025, 23:23 UTC

Ganancias

JBS NV 3Q EPS 52c >JBS

13 nov 2025, 23:23 UTC

Ganancias

JBS NV 3Q Sales $22.6B >JBS

13 nov 2025, 23:04 UTC

Charlas de Mercado

RBA Looks Set To Remain Sidelined For a While Yet -- Market Talk

13 nov 2025, 22:02 UTC

Ganancias

Nu Holdings 3Q Net $783M >NU

13 nov 2025, 22:01 UTC

Ganancias

Nu Holdings 3Q Rev $4.2B >NU

13 nov 2025, 21:51 UTC

Adquisiciones, fusiones, absorciones

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 3rd Update

13 nov 2025, 21:50 UTC

Ganancias

Disney Posts Roughly Flat Quarterly Revenue as TV Declines Continue -- 4th Update

13 nov 2025, 21:45 UTC

Adquisiciones, fusiones, absorciones

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- 2nd Update

13 nov 2025, 21:41 UTC

Adquisiciones, fusiones, absorciones

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- Update

13 nov 2025, 21:36 UTC

Adquisiciones, fusiones, absorciones

Paramount Plans to Bid for All of Warner Bros., Sources Say -- WSJ

13 nov 2025, 21:36 UTC

Adquisiciones, fusiones, absorciones

Paramount, Comcast, Netflix Among Potential Bidders That Have Looked at Warner Bros. Financials, Sources Say -- WSJ

13 nov 2025, 21:36 UTC

Adquisiciones, fusiones, absorciones

Paramount, Comcast, Netflix Prepare Bids for Warner As Deadline Approaches -- WSJ

13 nov 2025, 21:36 UTC

Adquisiciones, fusiones, absorciones

Netflix, Comcast Each Considering Pursuing Warner Bros. Studio, Streaming Assets, Sources Say -- WSJ

13 nov 2025, 21:36 UTC

Adquisiciones, fusiones, absorciones

Bids for Warner Bros. Discovery Due Next Week, Sources Say -- WSJ

13 nov 2025, 21:33 UTC

Charlas de Mercado

Banks See CAD Appreciation Through 2026, Trade Poses 'Clear' Risk -- Market Talk

13 nov 2025, 21:33 UTC

Ganancias

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares -- Barrons.com

13 nov 2025, 21:31 UTC

Ganancias

Applied Materials Stock Falls Despite Strong Earnings -- Barrons.com

13 nov 2025, 21:25 UTC

Ganancias

Figure Tech Solutions 3Q Rev $156.4M >FIGR

13 nov 2025, 21:25 UTC

Ganancias

Figure Tech Solutions 3Q EPS 34c >FIGR

13 nov 2025, 21:23 UTC

Ganancias

Intchains Group 3Q Rev $1.3M >ICG

13 nov 2025, 21:03 UTC

Ganancias

Applied Materials Sees 1Q Rev $6.35B-$7.35B >AMAT

13 nov 2025, 21:02 UTC

Ganancias

Applied Materials Sees 1Q Adj EPS $1.98-Adj EPS $2.38 >AMAT

13 nov 2025, 21:01 UTC

Ganancias

Applied Materials 4Q Rev $6.8B >AMAT

13 nov 2025, 21:01 UTC

Ganancias

Applied Materials 4Q Gross Margin 48.0% >AMAT

Comparación entre iguales

Cambio de precio

Artivion Inc Esperado

Precio Objetivo

By TipRanks

8.57% repunte

Estimación a 12 meses

Media 51.71 USD  8.57%

Máximo 58 USD

Mínimo 40 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Artivion Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

6

Comprar

1

Mantener

0

Vender

Sentimiento

By Acuity

171 / 374 Clasificación en Salud

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Artivion Inc

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
help-icon Live chat